Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ABILENE, Texas, July 14, 2026 (GLOBE NEWSWIRE) -- Duos Edge AI, Inc. (“Duos Edge AI”), a subsidiary of Duos Technologies Group, Inc. (Nasdaq: DUOT), announces the grand opening and community open...
-
New single-stock ETFs give investors amplified leveraged daily participation tied to NetApp, Inc. (NASDAQ: NTAP), Teradata Corporation (NYSE: TDC) and Bitdeer Technologies Group (NASDAQ: BTDR). NEW...
-
Scrum Alliance partners with The Pathwayz Group to launch an Executive Fluency for Agile Leaders microcredential course.
-
LAKEWOOD, NJ, July 14, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (NASDAQ: EZRA) today announced the launch of a proprietary AI agent built in-house for secure browser automation in...
-
Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the...
-
Commercial Launch Generates Rapid Growth in Platform Registrations, Global Audience Reach and Customer Engagement Within the First Weeks of Availability Torrance, Calif., July 14, 2026 (GLOBE...
-
Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Character-based AI Agents Market by Type, Interaction Mode, and Application - Global Forecast to 2032" has been added to ResearchAndMarkets.com's...
-
Dublin, July 14, 2026 (GLOBE NEWSWIRE) -- The "Liquid Cooling Data Center Infrastructure Products Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The...
-
Austin, United States, July 14, 2026 (GLOBE NEWSWIRE) -- Occupational Health Market Size was valued at USD 5.21 Billion in 2025 and is projected to reach USD 8.18 Billion by 2035, growing at a CAGR...
-
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as...